G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
123 hedge funds and large institutions have $582M invested in G1 Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 35 reducing their positions, and 25 closing their positions.
34% more capital invested
Capital invested by funds: $434M → $582M (+$148M)
23% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
2% less funds holding
Funds holding: 125 → 123 (-2)
17% less call options, than puts
Call options by funds: $10.9M | Put options by funds: $13.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$14M |
| 2 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$14M |
| 3 |
Two Sigma Investments
New York
|
+$12.9M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$9.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$22.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$15.3M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$11.5M |
| 4 |
Goldman Sachs
New York
|
-$8.55M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$8.54M |
GTHX Hedge Fund Activity: Q1 2021 in Review
123 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2021, worth a combined $582M — up 34% from $434M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of GTHX and 24 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 43 added.
The largest buyer was Compagnie Lombard Odier SCmA, opening a new position worth an estimated $14M. The largest seller was Wellington Management Group, exiting entirely with an estimated $22.3M sold.
- 123 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2021, down from 125 in Q4 2020.
- Funds reported $582M of G1 Therapeutics, Inc. Common Stock stock for Q1 2021, up 34% quarter-over-quarter.
- 24 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2021 and 25 closed out, a net change of -1 holder.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2021 was Compagnie Lombard Odier SCmA, an estimated $14M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2021 was Wellington Management Group, an estimated $22.3M sold.
Based on aggregated 13F filings for Q1 2021.